Status: Recruiting
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).
Participants needed: 30
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Dec 12, 2024Locations: 6
Eligibility criteria
Participants must have histologically- or cytologically-confirmed follicular-der... [+34]
Participants who have had chemotherapy, MKI or radiotherapy within 4 weeks. [+14]